Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells

被引:3
|
作者
Sang, Jun [1 ]
Liu, Chen-Kai [1 ]
Liu, Jue [1 ]
Luo, Guan-Cong [1 ]
Zheng, Wei-Ji [1 ]
Bai, Ya [1 ]
Jiang, De-Yun [1 ]
Pu, Jiang-Ni [1 ]
An, Su [1 ]
Xu, Tian-Rui [1 ]
机构
[1] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Ctr Pharmaceut Sci & Engn, Kunming 650500, Peoples R China
关键词
Drug resistance; Lipid peroxidation; Natural diterpenoid; Jolkinolide B; Thioredoxin reductase 1; THIOREDOXIN; FERROPTOSIS; DEATH; SENSITIVITY; CARCINOMA; APOPTOSIS;
D O I
10.1016/j.bcp.2024.116194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glutathione peroxidase 4 (GPX4) is a promising anticancer therapeutic target; however, the application of GPX4 inhibitors (GPX4i) is limited owing to intrinsic or acquired drug resistance. Hence, understanding the mechanisms underlying drug resistance and discovering molecules that can overcome drug resistance are crucial. Herein, we demonstrated that GPX4i killed bladder cancer cells by inducing lipid reactive oxygen speciesmediated ferroptosis and apoptosis, and cisplatin-resistant bladder cancer cells were also resistant to GPX4i, representing a higher half-maximal inhibitory concentration value than that of parent bladder cancer cells. In addition, thioredoxin reductase 1 (TrxR1) overexpression was responsible for GPX4i resistance in cisplatinresistant bladder cancer cells, and inhibiting TrxR1 restored the sensitivity of these cells to GPX4i. In vitro and in vivo studies revealed that Jolkinolide B (JB), a natural diterpenoid and previously identified as a TrxR1 inhibitor, potentiated the antiproliferative efficacy of GPX4i (RSL3 and ML162) against cisplatin-resistant bladder cancer cells. Furthermore, GPX4 knockdown and inhibition could augment JB-induced paraptosis and apoptosis. Our results suggest that inhibiting TrxR1 can effectively improve GPX4 inhibition-based anticancer therapy. A combination of JB and GPX4i, which is well-tolerated and has several anticancer mechanisms, may serve as a promising therapy for treating bladder cancer.
引用
收藏
页数:15
相关论文
共 12 条
  • [1] Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
    Wei He
    Yiqun Xia
    Peihai Cao
    Lin Hong
    Tingting Zhang
    Xin Shen
    Peisen Zheng
    Huanpei Shen
    Guang Liang
    Peng Zou
    Journal of Experimental & Clinical Cancer Research, 38
  • [2] Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells
    He, Wei
    Xia, Yiqun
    Cao, Peihai
    Hong, Lin
    Zhang, Tingting
    Shen, Xin
    Zheng, Peisen
    Shen, Huanpei
    Liang, Guang
    Zou, Peng
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [3] Deciphering the Comprehensive Structure-Activity Relationship of Sunshinamide for Breast Cancer Therapy through Dual Modulation of Apoptotic and Ferroptotic Pathways via TrxR1 and Gpx4 Inhibition
    Chatterjee, Akash
    Mondal, Joyanta
    Paul, Subhojit
    Sharma, Himangshu
    Goswami, Rajib Kumar
    Sen, Prosenjit
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (24) : 21952 - 21974
  • [4] Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin-resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway
    Ho, Jin-Nyoung
    Byun, Seok-Soo
    Lee, Sang Eun
    Youn, Je-In
    Lee, Sangchul
    ONCOLOGY REPORTS, 2019, 41 (04) : 2482 - 2490
  • [5] INHIBITION OF HSP90 SYNERGISTICALLY POTENTIATES ANTITUMOR EFFECT OF NVP-BEZ235 AND SATRAPLATIN COMBINATION THERAPY IN CISPLATIN-RESISTANT HUMAN BLADDER CANCER CELLS THROUGH THE DOWN-REGULATION OF AKT AND ERK SIGNALING
    Yoon, Cheol Yong
    Gong, Mi Kyung
    Kang, Dong Heok
    Kim, Myung Soo
    Jung, Won Sik
    Kim, Young Sik
    Cho, In Rae
    Choi, Young Deuk
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1318 - E1319
  • [6] Potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway
    He, Wei
    Cao, Peihai
    Xia, Yiqun
    Hong, Lin
    Zhang, Tingting
    Shen, Xin
    Zheng, Peisen
    Shen, Huanpei
    Zhao, Yunjie
    Zou, Peng
    FREE RADICAL RESEARCH, 2019, 53 (01) : 104 - 114
  • [7] Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2
    Park, Bong Hee
    Lim, Joung Eun
    Jeon, Hwang Gyun
    Seo, Seong Il
    Lee, Hyun Moo
    Choi, Han Yong
    Jeon, Seong Soo
    Jeong, Byong Chang
    ONCOTARGET, 2016, 7 (39) : 63870 - 63886
  • [8] Yi-qi-hua-yu-jie-du decoction induces ferroptosis in cisplatin-resistant gastric cancer via the AKT/GSK38/NRF2/GPX4 axis
    Huang, Wenjie
    Wen, Fang
    Yang, Peipei
    Li, Ye
    Li, Qiurong
    Shu, Peng
    PHYTOMEDICINE, 2024, 123
  • [9] Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
    Kim, JK
    Kim, KD
    Lee, E
    Lim, JS
    Cho, HJ
    Yoon, HK
    Cho, MY
    Baek, KE
    Park, YP
    Paik, SG
    Choe, YK
    Lee, HG
    CANCER LETTERS, 2004, 212 (01) : 61 - 70
  • [10] Regulation of AMPK-dependent MDR1 expression by resveratrol in cisplatin-resistant human bladder cancer T24 cells via attenuating NF-κB and CRE transcriptional activity
    Hong, S. H.
    Han, M. H.
    Park, C.
    Ji, S. Y.
    Jeong, J. W.
    Choi, E. O.
    Choi, Y. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S58 - S58